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Abstract
Background: Tumor immune-escape has been related to the ability of cancer cells to inhibit T cell activation and
dendritic cell (DC) differentiation. We previously identified a tumor initiating population, expressing the mesenchymal
marker CD105, which fulfills the criteria for definition as cancer stem cells (CD105+ CSCs) able to release extracellular
vesicles (EVs) that favor tumor progression and metastases. The aim of the present study was to compare the ability of
renal CSCs and derived EVs to modulate the behavior of monocyte-derived DCs with a non-tumor initiating renal
cancer cell population (CD105- TCs) and their EVs.
Methods: Maturation of monocyte-derived DCs was studied in presence of CD105+ CSCs and CD105- TCs and their
derived EVs. DC differentiation experiments were evaluated by cytofluorimetric analysis. T cell proliferation and ELISA
assays were performed. Monocytes and T cells were purified from peripheral blood mononuclear cells obtained from
healthy donors.
Results: The results obtained demonstrate that both CD105+ CSCs and CD105- TCs impaired the differentiation
process of DCs from monocytes. However, the immune-modulatory effect of CD105+ CSCs was significantly greater
than that of CD105- TCs. EVs derived from CD105+ CSCs and in less extent, those derived from CD105- TCs retained the
ability to impair monocyte maturation and T cell activation. The mechanism has been mainly related to the expression
of HLA-G by tumor cells and to its release in a form associated to EVs. HLA-G blockade significantly reduced the
inhibitory effect of EVs on DC differentiation.
Conclusions: In conclusion, the results of the present study indicate that renal cancer cells and in particular CSCs and
derived EVs impair maturation of DCs and T cell immune response by a mechanism involving HLA-G.
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Background
Tumor is a complex structure constituted by cancer cells
with different stages of differentiation. Cancer cells may
communicate with surrounding cells to develop an
environment favorable to its development. Several stud-
ies have suggested that tumor microenvironment may
promote oncogenic progression [1]. In renal cell carcin-
omas, we identified a tumor initiating population,
expressing the mesenchymal marker CD105, which ful-
fills the criteria for definition as cancer stem cells (CSCs)
[2]. Namely, this population retains clonogenic ability,
expresses Nanog, Nestin and Oct3-4 stem cell markers,
and is able to grow in spheres and to induce serially
transplantable tumors starting from a number of cells as
low as 100 cells [2].
We previously found that extracellular vesicles (EVs)
released by renal CD105+ CSCs, but not EVs derived
from a more differentiated tumor cell population
(CD105- TCs), are able to modify tumor microenviron-
ment and to promote development of a lung pre meta-
static niche [3].
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Several studies indicate that tumor released EVs may
orchestrate tumor progression stimulating proliferation,
angiogenesis, metastasis formation and immune-escape
[4–10]. EVs contain proteins, microRNAs and mRNAs
that may be transferred to recipient cells and induce
phenotypic and epigenetic changes leading to tumor cell
progression and immune-escape [11–14]. In cancer pa-
tients the amount of serum-EVs were shown to correlate
with a poor prognosis [15]. In addition, tumor-derived
EVs, retaining the signature of the cells of origin, may be
exploited as a diagnostic tool in cancer [16].
The interaction between tumor and dendritic cells
(DCs) has a relevant role in the immune response to
tumor antigens. DCs are the most effective antigen pre-
senting cells able to prime naïve T lymphocytes [17]. DCs
switch from an immature to an activated state thorough a
maturation process. The inhibition of DC maturation has
been involved in tumor immune-escape [18]. Several sol-
uble factors have been involved in down regulation of DC
activation including IL-6, IL-10, PGE2, soluble HLA-G
(sHLA-G) and EVs [10, 19–24].
The aim of the present study was to compare the ability
of renal CSCs and derived EVs to modulate the behavior
of monocyte derived- DCs with a non-tumor initiating
renal cancer cell population and their EVs. Herein, we
evaluated whether co-incubation with CD105+ CSCs and
derived EVs interfere with monocyte differentiation into
DCs. In fact, immature DCs have been shown to promote
induction of tolerance [25].
Results
Human CD105+ CSCs suppress monocyte-derived DC
differentiation and maturation
To evaluate inhibition of DC differentiation, monocytes
were cultured in the presence of CD105+ CSCs and of
CD105- TCs. Monocytes, isolated by adhesion (CD14+:
87.4 ± 3.5 %, not shown) from Peripheral Blood Mono-
nuclear Cells (PBMCs), were cultured with Granulocyte-
Macrophage Colony-Stimulating Factor (GM-CSF) and
IL-4 in the presence or absence of CD105+ CSCs or
CD105- TCs. After 4 days of culture, in order to induce
the complete differentiation and maturation of DCs,
lipopolysaccharide (LPS) was added. After 7 days, DCs
(CTL DC) underwent a complete maturation and
acquired their characteristic morphology and appropri-
ate marker expression (Fig. 1a). Properly matured DCs
significantly reduced the expression of monocyte/macro-
phage CD14 marker (5.7 ± 4.9 %) and acquired the expres-
sion of CD83 (20.1 ± 5.9 %). Moreover, they increased the
expression of CD80, CD86 and HLA-DR (76.1 ± 10.8 %,
87.0 ± 8.7 % and 95.1 ± 7.1 % respectively) and expressed
the activation markers CD1a and CD40 (87.9 ± 5.2 %,
23.8 ± 15.5 % respectively) (Fig. 1a).
Co-culture with CD105+ CSCs or CD105- TCs inter-
fered with the phenotype of monocyte-derived cells
(Fig. 1a). Monocyte-derived cells in the presence of
CD105+ CSCs (CD105+ Mo) or of CD105- TCs (CD105-
Mo) maintained CD14 marker (CD105+ Mo: 12.0 ±
3.5 % and CD105- Mo: 22.5 ± 1.2 %) and did not acquire
activation markers such as CD83 (CD105+ Mo: 1.3 ±
0.5 % and CD105- Mo: 2.0 ± 1.1 %) and CD40 (CD105+
Mo: 1.6 ± 0.5 % and CD105- Mo: 3.2 ± 3.3 %). Similarly,
the antigen-presenting molecule HLA-DR was signifi-
cantly lower in presence of CD105+ CSCs (64.6 ± 16.1 %)
and CD105- TCs (76.5 ± 10.8 %) in comparison with
control DCs. However, the inhibitory effect was signifi-
cantly higher in presence of CD105+ CSCs than CD105-
TCs. The percentage of monocyte-derived cells positive
for costimulatory molecules CD80 (CD105+ Mo: 30.0 ±
16.0 % and CD105- Mo: 50.2 ± 13.8 %) and CD86
(CD105+ Mo: 55.5 ± 6.4 % and CD105- Mo: 69.5 ±
15.4 %) and for the specific dendritic marker CD1a
(CD105+ Mo: 71.0 ± 13.2 % and CD105- Mo: 92.0 ±
4.0 %) were significantly reduced by CD105+ CSCs com-
pared to CD105- TCs. Both CD105+ CSCs and CD105-
TCs significantly reduced also the expression of adhe-
sion molecules such as integrin α4 and α5, involved in T
cell contact, by monocyte-derived cells (Fig. 1a). CD105+
CSCs were significantly more effective than CD105- TCs
in reducing the percentage of integrin α4 and α5 positive
cells on monocyte-derived cells (integrin α4: CD105+
Mo: 9.0 ± 6.2 % and CD105- Mo: 31.0 ± 14.3 %; integrin
α5: CD105+ Mo: 33.3 ± 14.4 % and CD105- Mo: 57.7 ±
6.6 %). The mean fluorescence intensity (MFI) confirmed
the inhibitory effect of CD105+ CSCs in respect to con-
trol DCs (Fig. 1b and Additional 1: Table S1). The
inhibitory effect of CD105- TCs was significant only for
some markers (CD80, CD86, CD40, HLA-DR and α5
integrin). When CD105+ CSCs were compared with
CD105- TCs, MFI of monocyte-derived cells was signifi-
cantly reduced for costimulatory, activation and adhe-
sion molecules such as CD14, CD83, CD80, HLA-DR,
CD1a, α4 integrin and CD54 (Fig. 1b and Additional 1:
Table S1).
Monocyte-derived cells cultured with CD105+ CSCs failed
to induce T cell proliferation
Mature DCs were the main antigen presenting cells and
were able to induce T cell response and activation. LPS-
stimulated DCs were capable to induce CD3+ lymphocyte
proliferation. The preconditioning of monocyte-derived
cells by co-culture with CD105+ CSCs significantly im-
paired their ability to stimulate CD3+ lymphocyte prolifer-
ation (Fig. 1c). The co-culture of monocyte-derived cells
with CD105+ CSCs induced the release of IL-10 soluble
factor (122.5 ± 25.6 pg/ml) (Fig. 2a). On the contrary, the
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Fig. 1 Renal cancer cells suppressed monocyte-derived DC differentiation and their ability to stimulate T cell proliferation. a Mean percentage
expression ± SD of CD14, CD83, α5 integrin, CD40, α4 integrin, CD80, CD86, HLA-DR, CD1a and CD54 by monocyte-derived DCs differentiated in
the presence or in absence (CTL DC) of CD105+ CSCs (CD105+ Mo) or CD105- TCs (CD105- Mo). Results were obtained from 6 independent experiments.
ANOVA with Newman Keuls multicomparison test was performed: *p< 0.05 CD105+ Mo and CD105- Mo versus CTL DC; § p< 0.05 CD105+ Mo versus
CD105- Mo. b MFI ± SD of CD14, CD83, CD80, CD40, α4 integrin, CD54, α5 integrin, CD86, HLA-DR and CD1a of monocyte-derived DCs differentiated in
the presence or in absence (CTL DC) of CD105+ CSCs (CD105+ Mo) or CD105- TCs (CD105- Mo). Results were obtained from 6 independent experiments.
ANOVA with Newman Keuls multicomparison test was performed: *p< 0.05 CD105+ Mo and CD105- Mo versus CTL DC; § p< 0.05 CD105+ Mo versus
CD105- Mo. c Monocyte-derived DCs differentiated in the presence or in absence (CTL DC) of CD105+ CSCs (CD105+ Mo) or CD105- TCs
(CD105- Mo) were plated at cell concentration of 2x104 with 1x105 T CD3+ lymphocytes. Forty eight hours later T-cell proliferation was
assessed. Data are expressed as mean ± SD of percent variation of T-cell proliferation in the presence of DCs differentiated in presence of renal
cancer cells in respect to T-cell proliferation in presence of DCs matured in the absence of cells (established as 100 %). Results were obtained
from 5 independent experiments. ANOVA with Newman Keuls multicomparison test was performed: *p < 0.05 CD105+ Mo versus all the
other conditions
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co-culture with CD105- TCs induced only a slight increase
of IL-10 production (11.3 ± 0.5 pg/ml) (Fig. 2a).
sHLA-G was released in cell free supernatant of
monocyte-derived cells co-cultured with CD105+ CSCs
The non-classical human leukocyte antigen HLA-G was
evaluated. By ELISA assay, the soluble HLA-G (sHLA-G)
was barely detectable in cell free supernatants of renal
cancer cells (not shown) and of fully differentiated DCs
(Fig. 2b). On the contrary, the level of sHLA-G was sig-
nificantly increased in supernatant of monocyte-derived
cells co-cultured with CD105+ CSCs (12.1 ± 2.3 U/ml)
compared with CD105- TCs (1.8 ± 1.6 U/ml) or with con-
trol DCs (2.2 ± 2.1 U/ml) (Fig. 2b). The expression of
HLA-G by renal cell carcinomas and the presence of its
soluble form in plasma of patients were previously
described [26, 27]. CD105+ CSCs in basal condition
expressed the membrane bound isoform HLA-G1
composed by 3 globular domains. In CD105- TCs, the iso-
form HLA-G1 was barely detectable (Fig. 3a and b). The
cytoplasmic isoform HLA-G1/G5 was expressed at very
low level by both CD105+ CSCs and by CD105- TCs
(Fig. 3a). When CD105+ CSCs were co-cultured in trans-
well for 1 week with monocyte-derived cells, they up regu-
lated the expression of HLA-G1 isoform as well as of the
cytoplasmic isoform HLA-G1/G5 (Fig. 3c). No significant
up-regulation was observed in CD105- TCs co-cultured
with monocyte-derived cells. On the other hand,
monocyte-derived cells showed a slight increase of HLA-
G1 after co-culture with CD105+ CSCs (Fig. 3d). These
data suggest that the presence of sHLA-G in the super-
natant of co-culture is mainly due to secretion by CD105+
renal CSCs.
EVs contributed to the inhibitory effect of renal CSCs on
monocyte-derived cell differentiation by carrying HLA-G
As shown in Fig. 4a, both EVs derived from CD105+
CSCs and CD105- TCs interfered with the DC differenti-
ation process. Stimulation with EVs significantly abro-
gated the expression of activation markers CD83
(CD105+ EV Mo: 5.6 ± 2.0 % and CD105- EV Mo: 1.6 ±
1.5 %) and CD40 (CD105+ EV Mo: 1.6 ± 1.5 % and
CD105- EV Mo: 1.0 ± 1.7 %) by monocyte-derived cells.
At the same time, monocyte-derived cells maintained
CD14 expression (CD105+ EV Mo: 37.3 ± 7.7 % and
CD105- EV Mo: 20.6 ± 12 %) (Fig. 4a). However, the
inhibitory effect of EVs derived from CD105+ CSCs was
significantly greater than that of EVs derived from
CD105- TCs with particular regard to the maintenance
of CD14 expression. Stimulation with CD105+ EVs, but
not with CD105- EVs, strongly reduced the costimulatory
molecules such as CD80 (CD105+ EV Mo: 26.3 ± 20.7 %
and CD105- EV Mo: 61.3 ± 19.1 %) and CD86 (CD105+
EV Mo: 47.3 ± 7.2 % and CD105- EV Mo: 72.0 ± 21.4 %)
and the antigen presenting molecule HLA-DR (CD105+
EV Mo: 58.3 ± 7.0 % and CD105- EV Mo: 82.2 ± 15.8 %)
on monocyte-derived cells compared with DCs (CTL DC)
(Fig. 4a). Furthermore, the inhibitory effect of CD105+
EVs was evident also on the reduction of adhesion mol-
ecule CD54 (CD105+ EV Mo: 73.2 ± 20.7 % and CD105-
EV Mo: 85.3 ± 11.3 %) and α5 integrin (CD105+ EV Mo:
40.3 ± 13.6 % and CD105- EV Mo: 58.6 ± 17.2 %) on
monocyte-derived cells (Fig. 4a).
The interference of DC differentiation and maturation
process induced by CD105+ EVs appeared also clear by
analysing the fluorescence intensity expressed as MFI
(Fig. 4b and Additional 2: Table S2). CD105+ EVs signifi-
cantly reduced the MFI of CD40, α5 integrin, CD80,
CD86, HLA-DR and CD54 on monocyte-derived cells
compared with CD105- EVs or with control DCs (Fig. 4b
and Additional 2: Table S2).
Fig. 2 Co-culture of monocyte-derived cells with CD105+ CSCs
induced the release of IL-10 and sHLA-G. Cell supernatants were
harvested to detect IL-10 (a) and sHLA-G (b) production by ELISA,
after 7 days of co-culture of monocyte-derived cells in the presence
or absence (CTL DC) of renal cancer cells (CD105+ CSCs and CD105-
TCs). Results were obtained from 3 independent experiments and
expressed as mean ± SD. ANOVA with Newman Keuls multicomparison
test was performed: ** p < 0.001 CD105+ CSC Mo versus all the
other conditions
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DCs differentiated in the presence of EVs shed by
CD105+ CSCs failed to induce T cell proliferation (Fig. 4c).
The pretreatment of monocyte-derived cells with CD105+
EVs significantly impaired the ability of these cells to stimu-
late CD3+ lymphocyte proliferation (Fig. 4c). Monocyte-
derived cells stimulated with CD105+ EVs and CD105- EVs
released significant amount of IL-10 (191.6 ± 91.1 pg/ml for
CD105+ EVs and 141 ± 70.3 pg/ml for CD105- EVs) com-
pared with control DCs (1.7 ± 10.1 pg/ml).
The involvement of HLA-G carried by EVs on the inhibitory
effect of CD105+ EVs on monocyte-derived DC
differentiation
The level of sHLA-G was tested on supernatant of
monocyte-derived cells stimulated with EVs. Monocyte-
derived cells treated with CD105+ EVs showed the
presence of sHLA-G in the supernatant of culture after
7 days (14.5 ± 2.3 U/ml) (Fig. 5a); a lower level of
sHLA-G was observed using CD105- EVs as stimulus
(7.4 ± 3.2 U/ml).
The presence of HLA-G within EVs was demonstrated
by Western Blot (Fig. 5b); both CD105+ EVs and CD105-
EVs carried HLA-G. The amount was greater in EVs
shed by CD105+ CSCs than by CD105- TCs (Fig. 5b).
To demonstrate a relevant role of sHLA-G in the
monocyte-derived DC differentiation process, a blocking
antibody was added to monocyte-derived cells plus
CD105+ EVs. The presence of blocking antibody partially
reverted the inhibitory effect of EVs shed by CD105+
CSCs (Fig. 6). It was observed that anti-HLA-G antibody
abrogated the maintenance of the monocyte/macro-
phage marker CD14 induced by CD105+ EVs on
Fig. 3 HLA-G expression and up-regulation by CD105+ CSCs. a Representative cytofluorimetric analysis of HLA-G expression on CD105+ CSCs and
CD105- TCs membrane (G1) and intra-cytoplasmic (G1/G5) staining in basal culture condition (n = 4). b Western Blot analyses confirmed the presence
of several isoforms of HLA-G in CD105+ CSCs and CD105- TCs. c Representative cytofluorimetric analysis of membrane (G1) and intra-cytoplasmic (G1/
G5) staining of HLA-G on CD105+ CSCs and CD105- TCs after 7 days of co-culture with monocyte-derived cells (n = 4). d Representative cytofluorimetric
analysis of HLA-G expression on monocyte-derived cell membrane (G1) and intra-cytoplasmic (G1/G5) in basal condition and after co-culture with
CD105+ CSCs and CD105- TCs (n = 4)
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monocyte-derived cells (CD105+ EV: 46.4 ± 3.0 % and
CD105+ EV + anti-HLA-G: 7.5 ± 2.1 %) (Fig. 6a). In
addition, the anti-HLA-G antibody significantly reverted
the MFI reduction of CD86 (CD105+ EV: 150 ± 14 %
and CD105+ EV + anti-HLA-G: 184 ± 19 %), HLA-DR
(CD105+ EV: 123 ± 11 % and CD105+ EV + anti-HLA-G:
179 ± 16 %), CD1a (CD105+ EV: 103 ± 4 % and CD105+
EV + anti-HLA-G: 137 ± 7 %) and α5 integrin (CD105+
EV: 89 ± 9 % and CD105+ EV + anti-HLA-G: 120 ± 12 %)
on monocyte-derived cells (Fig. 6b).
Discussion
Monocyte-derived DCs are considered the end differen-
tiation step of blood monocytes. This process requires
transition from an immature to a mature stage and has a
pivotal role in initiating immunity. During this process,
Fig. 4 EVs shed by renal cancer cells inhibited monocyte-derived DC differentiation and their ability to stimulate T cell proliferation. a Mean percentage
expression ± SD of CD80, CD86, HLA-DR, CD1a, α4 integrin, CD54, α5 integrin, CD14, CD83 and CD40 by monocyte-derived DCs differentiated
in the presence or in absence (CTL DC) of CD105+ EVs (CD105+ EV Mo) or CD105- EVs (CD105- EV Mo). Results were obtained from 6 independent
experiments. ANOVA with Newman Keuls multicomparison test was performed: *p < 0.05 CD105+ EV Mo and CD105- EV Mo versus CTL DC; § p < 0.05
CD105+ EV Mo versus CD105- EV Mo. b MFI ± SD of CD83, CD40, α5 integrin CD80, CD86, HLA-DR and CD54 of monocyte-derived DCs differentiated
in the presence or in absence (CTL DC) of CD105+ EVs (CD105+ EV Mo) or CD105- EVs (CD105- EV Mo). Results were obtained from 6 independent
experiments. ANOVA with Newman Keuls multicomparison test was performed: *p < 0.05 CD105+ EV Mo and CD105- EV Mo versus CTL DC; § p < 0.05
CD105+ EV Mo versus CD105- EV Mo. c Monocyte-derived DCs differentiated in the presence or in absence (CTL DC) of CD105+ EVs (CD105+ EV Mo)
or CD105- EVs (CD105- EV Mo) were plated at cell concentration of 2x104 with 1x105 T CD3+ lymphocytes. Forty eight hours later T-cell proliferation
was assessed. Data are expressed as mean ± SD of percent variation of T-cell proliferation in the presence of DCs differentiated in the presence of renal
cancer cells in respect to T-cell proliferation in presence of DCs matured in the absence of EVs (established as 100 %). Results were obtained from 4
independent experiments. ANOVA with Newman Keuls multicomparison test was performed: *p < 0.05 CD105+ EV Mo versus all the other conditions
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DCs up regulate many surface molecules such as costi-
mulatory and activator molecules [19]. The principal
role of mature DCs is the antigen presentation and the
activation of naïve T lymphocytes [28].
The results of the present study demonstrate that
renal cancer cells impaired the differentiation process of
DCs from monocytes. Several soluble factors including
cytokines and chemokines may influence DC phenotype
[19–24]. Here we demonstrated a contribution of EVs in
this process. Monocytes co-cultured with CD105+ CSCs
or CD105- TCs did not up regulate the antigen-
presenting molecule HLA-DR and did not acquire acti-
vation markers such as CD83 and CD40, expressed by
appropriately differentiated and matured DCs. The
immune-modulatory effect of CD105+ CSCs was signifi-
cantly more efficient than that of CD105- TCs. In
particular, the presence of CD105+ CSCs reduced the ac-
quisition of the specific dendritic marker CD1a and
down regulated the expression of costimulatory mole-
cules (CD80 and CD86) and of adhesion molecules (α4
and α5 integrin and CD54).
Strong evidence indicates that tumor growth is not
just determined by malignant cancer cells, but requires a
favourable microenvironment generated by many non-
tumor cells such as fibroblasts, endothelial cells and im-
mune cells [29]. Recent studies have suggested that
tumour cells possess strong capacity to modulate the
immune-response by inhibition of T cells, NK response
and DC differentiation and by promoting myeloid de-
rived suppressor cells with T cell inhibitory capacity
[30–32]. It is generally recognized that tumors contain
heterogeneous populations of tumor cells with different
proliferation and differentiation potential [33, 34]. The
relative contribution of these populations to immune-
suppression has not yet been completely defined. We
herein demonstrated that the CD105+ CSC population
was the main responsible for making monocyte-derived
cells unable to stimulate T cell proliferation.
Cancer cells are known to release a wide range of soluble
factors in order to promote tumor progression. Previous
studies demonstrated that tumor cells were able to shed
large amount of EVs [35] that may act on neighbouring or
distant cells changing their phenotype [36–40]. EVs re-
leased from CSCs were found to modify the tumor micro-
environment promoting vascularization and inducing lung
pre-metastatic niche formation [3]. Moreover, we recently
found that CSC-derived EVs induced a pro-tumorigenic
phenotype in mesenchymal stromal cells [41].
In the present study we demonstrated that CSC derived
EVs are the main mediators of the inhibitory effect on
monocyte differentiation and maturation into DCs. EVs
shed from CD105+ CSCs inhibited DC differentiation
process whereas EVs derived from CD105- TCs only par-
tially interfered with DC differentiation. In the presence of
CD105+ EVs, monocyte-derived cells retained the mono-
cyte/macrophage CD14 marker and strongly reduced the
expression of HLA-DR, costimulatory molecules and ad-
hesion molecules. In addition, DCs differentiated in the
presence of CD105+ and not CD105- EVs, significantly
reduced proliferation of CD3 lymphocytes.
HLA-G carried by EVs was shown to contribute to this
inhibitory effect. HLA-G is a non-classical HLA-class I
molecule with a low polymorphism and a restricted tis-
sue distribution. Originally, HLA-G was described to
protect the fetus against the maternal immune system
[42]. HLA-G was shown to suppress the function of
NKs, T cells and DCs [43]. Moreover, HLA-G is also in-
volved in cancer immune-escape [44–47]. In particular,
HLA-G has been shown to be up-regulated in 50 % of
clear cell renal cell carcinomas and the presence of its
Fig. 5 Treatment of monocyte-derived cells with CD105+ EVs
induced a release of sHLA-G. a Supernatants were harvested to
detect sHLA-G production by ELISA, after 7 days of culture of
monocyte-derived cells stimulated with EVs shed by renal cancer
cells (CD105+ CSCs and CD105- TCs). Results were obtained from 3
independent experiments and expressed as mean ± SD. ANOVA with
Newman Keuls multicomparison test was performed: ** p < 0.001
CD105+ EV Mo versus all the other conditions. b Representative
Western Blot analysis showing the presence of HLA-G and Alix
within EVs. Hsp90 was used as normalization. Four experiments were
performed with similar results
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soluble form has been detected in plasma of these pa-
tients [26, 27]. CD105+ CSCs expressed high level of
HLA-G compared with CD105- TCs. The co-culture
with immune cells significantly increased HLA-G ex-
pression by CD105+ CSCs as well as the soluble form.
We also found that sHLA-G was mainly associated with
EVs released from CD105+ CSCs and in less extent with
those released from CD105- TCs. Experiments with anti-
HLA-G blocking antibody demonstrated that the inhibi-
tory effect of CD105+ EVs on monocyte maturation was
significantly reduced suggesting that EV-carried HLA-G
plays a relevant immune-modulatory role.
Conclusions
In conclusion, the results of the present study indicate
that renal cancer cells and derived EVs impair matur-
ation of DCs and T cell immune response. This effect
was mainly ascribed to the CSC population and to the
release of HLA-G-carrying EVs.
Methods
The study has been approved by the ethic Committee of
the Azienda Ospedaliera Universitaria, Città della Salute
e della Scienza, Torino (N. 168/2014).
Renal cancer cells
CD105+ CSC clones and CD105- TCs were previously
isolated and characterized [2] and were cultivated in
DMEM LG (Invitrogen, Paisly, UK), with insulin-
transferrin-selenium, 10-9 M dexametasone, 100 U peni-
cillin, 1000 U streptomycin, 10 ng/ml Epidermal Growth
Factor (all from Sigma-Aldrich, St. Louis, MO, USA)
and 5 % FCS (EuroClone, Wetherby, UK). To avoid the
presence of non-neoplastic contaminating cells, CD105+
CSCs were grown in expansion medium without serum
or were cloned. Three clones originating from 3 differ-
ent renal cell carcinomas were used. The CD105- popu-
lation was unable to generate clones [2]. CD105+ CSCs
expressed the CD105 mesenchymal marker and other
mesenchymal stromal cell markers such as CD90, CD44,
CD73, CD29, CD146 and vimentin. Additionally they
were positive for the embryonic renal marker Pax2 as
well as Nanog, Oct3-4, Musashi, and Nestin. They were
clonogenic and generated spheres in non-adhesive cell
culture medium. CD105+ CSCs displayed the ability to
initiate tumors and generate serially transplantable tu-
mors with a number of cells as low as 100 cells/mouse
recapitulating the histological pattern of the tumor of
origin [3, 41]. As previously described, CD105+ CSCs
were negative for endothelial or haematopoietic markers
[2, 3, 41].
EV isolation and characterization
EVs were obtained from cell supernatants by ultracentri-
fugation as previously described [3]. In brief, CD105+
CSCs and CD105- TCs were cultured overnight in RPMI
(Euroclone). Cell supernatant was centrifuged twice at
3000 g for 10 min to remove cell debris and then
Fig. 6 The use of specific blocking antibody against HLA-G partially reverted the inhibitory effect on monocyte-derived DC differentiation induced
by CD105+ CSC EVs. a Mean percentages ± SD of CD14 expression by monocyte-derived DCs stimulated with CD105+ EVs in the presence or in
absence (CD105+ EV Mo) of specific blocking antibody against HLA-G (CD105+ EV Mo + anti HLA-G). Results were obtained from 2 independent
experiments. T Student test was performed: *p < 0.05 CD105+ EV Mo versus CD105+ EV Mo + anti HLA-G. b MFI ± SD of CD80, CD86, ΗLA-DR,
CD1a and α5 integrin of monocyte-derived DCs stimulated with CD105+ EVs in the presence or in absence (CD105+ EV Mo) of specific blocking
antibody against HLA-G (CD105+ EV Mo + anti HLA-G). T Student test was performed: *p < 0.05 CD105+ EV Mo versus CD105+ EV
Mo + anti HLA-G
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ultracentrifuged at 100.000 g (Beckman Coulter Optima
L-90 K ultracentrifuge, Brea, CA, USA) for 2 h at 4 °C.
EVs were stored in serum free RPMI supplemented with
10 % DMSO at -80 °C. EV number was quantified by
NanoSight LM10 instrument (NanoSight Ltd., Amesbury,
UK) equipped with the nanoparticle tracking analysis
(NTA) 2.0 analytic software. The protein content of EV
preparations was quantified by Quantifluor (Promega)
using NanoOrange Protein Quantitation Kit (Life Tech-
nologies, Carlsbad, CA). Cytofluorimetric analysis was
performed by Guava easyCyte Flow Cytometer (Millipore,
Billerica, MA, USA) and analyzed with InCyte software
using the following FITC- or PE- conjugated antibodies:
CD44, CD105, α5 integrin, α6 integrin (Miltenyi Biotec,
Bergisch Gladbach, Germany), CD73, CD29, CD90 and
CD146 (BD Biosciences) [48]. FITC or PE mouse isotypic
IgG (Miltenyi Biotec) were used as control (Additional 3:
Figure S1).
Peripheral blood mononuclear cell isolation
PBMCs were obtained from healthy donors (n = 5 males;
n = 9 females; age 25-50 years old). All subjects gave
informed consent and the study was approved by the in-
ternal Review Board of Blood Bank, Azienda Ospedaliera
Universitaria, Città della Salute e della Scienza. PBMCs
were isolated by centrifugation over Histopaque-1077
(Sigma).
DC differentiation
Monocytes were isolated by plastic adherence. PBMCs
were plated at the concentration of 5x106 cells/ml in DC
differentiation medium, composed by RPMI supple-
mented with 10 % FCS, 20 ng/ml of IL-4 (Sigma) and
50 ng/ml of GM-CSF (Sigma), in 6-well flat-bottomed
plates, and left to adhere overnight [49]. Non-adherent
cells were removed the day after and the purity of
monocyte population was quantified by positive staining
for CD14 (CD14+: 87.4 ± 3.5 %, not shown), assessed by
FACS analysis. Monocytes were co-cultured in the pres-
ence of 1x105 CD105+ CSCs or CD105- TCs seeded in
transwell (1 μm-pore) or with the amount of EVs
released by the same number of cells. CD105+ CSCs re-
lease a mean of 913 ± 40 particles/cell and CD105- TCs
shed a mean of 1075 ± 65 particles/cell, so we stimulated
monocytes with 0.9x108 CD105+ EVs and with 1.0x108
CD105- EVs. After 2 days, 1/3 of the medium was
replaced and after 4 days, 200 ng/ml of LPS (Sigma) was
added to the culture. At this time, renal cancer cells
were replaced (1x105 cells/transwell) and the stimulus
with EVs was added again. Complete differentiation was
reached after 7 days. The DC differentiation was assessed
after 7 days of culture using FITC, PE and APC conju-
gated antibodies (all from Becton Dickinson Bioscence,
San Josè, CA) for CD14, CD80, CD86, HLA-DR, CD1a,
CD83, CD40, CD54, α4 and α5 integrin. Data were
expressed as percentage of positive cells ± SD and as geo-
metric mean of MFI ± SD.
In selected experiments, to test the functional role of
HLA-G, the differentiation of monocytes was performed
in presence of CD105+ EVs plus the specific neutralizing
antibody HLA-G (clone 87-G, EXBIO, Praha, Czech
Republic) at the concentration of 10 μg/ml added twice.
T cell isolation and proliferation
CD3 positive lymphocytes were sorted from PBMCs using
anti-CD3 magnetic beads (Miltenyi Biotec). T cells were
used for proliferation assay. Completely differentiated
DCs in the presence or not of tumor cells or EVs were
treated with 50 μg/ml mitomycin C (Sigma) in order to
block their proliferation and cultured in triplicate in a
concentration of 2x104 in 96 well flat-bottomed plate with
1x105 allogeneic CD3+ lymphocytes [21]. As positive con-
trol CD3+ cells were treated with 10 ng/ml of PMA (phor-
bol 12-myristate 13-acetate, Sigma). Proliferation rate was
analyzed after 3 days of co-culture using 5-bromo-2’-de-
oxy-uridine (BrdU) incorporation kit (Roche, Basel,
Switzerland). Optical density was measured with an ELISA
reader at 405 nm. Data are expressed as mean ± SD of per-
cent variation of T-cell proliferation in the presence of
DCs differentiated with renal cancer cells in respect to T-
cell proliferation induced by DCs matured in the absence
of cells (established as 100 %).
ELISA assays
sHLA-G and IL-10 were quantified in the cell superna-
tants of monocyte-derived cell culture in absence or in
presence of CD105+ CSCs and CD105- TCs by enzyme-
linked immunosorbent assay (ELISA, R&D System,
Minneapolis, MN).
Detection of HLA-G by FACS
The expression of HLA-G, (dilution 1:20) on renal can-
cer cells and on monocyte-derived cells was evaluated
by FACS analysis using the specific MEMG/11 antibody
(native form for human HLA-G1, EXBIO, Praha, Czech
Republic) and MEMG/9 (native form for human HLA-G1
and for soluble HLA-G5 EXBIO, Praha, Czech Republic).
Extracellular and intra-cellular staining were used to study
membrane bound and intra-cytoplasmatic HLA-G protein.
Western Blot
HLA-G, ALIX and Hsp90 expression was analyzed by
Western Blot. In brief, cells and EVs were lysed in RIPA
buffer containing a cocktail of protease inhibitors and
the quantification was performed using Bradford. EV
proteins or total cell lysates were solubilized in Laemli
sample buffer at 95 °C, under reducing conditions and
separated in 4-15 % sodium dodecyl sulfate (SDS)-
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polyacrylamide gel electrophoresis. Nitrocellulose mem-
branes (Bio-Rad laboratories) were blotted with antibodies
specific for HLA-G (1:200), Hsp90 (1:200) and ALIX
(1:200) (from Santa Cruz Biotechnology, Santa Cruz CA)
and with anti-mouse or anti-rabbit horseradish peroxidase
(HRP)-conjugated antibodies (1:3000) (Pierce, Waltham,
MA) and developed using ECL plus detection reagents
(GE Healthcare, Piscataway, NJ). Densitometry analysis
was performed using Quantity One image acquisition and
analysis software (Bio-Rad laboratories).
Statistical analysis
Results are expressed as mean ± SD. Statistical analysis
was performed by using the t test, ANOVA with
Newmann-Keuls, or ANOVA with Dunnet’s multicompar-
ison tests when appropriate. A p value of <0.05 was con-
sidered significant.
Additional files
Additional 1: Table S1. Mean Fluorescence Intensity (MFI) of
monocyte-derived cells cultured in presence or absence of renal cancer
cells (CD105+ CSCs and CD105- TCs). (DOCX 13 kb)
Additional 2: Table S2. Mean Fluorescence Intensity (MFI) of
monocyte-derived cells stimulated with or without EVs shed by CD105+
CSCs and CD105- TCs. (DOCX 14 kb)
Additional 3: Figure S1. EVs characterization. A. Representative size
distribution of EVs shed by CD105+ CSCs and CD105- TCs obtained using
NanoSight LM10 instrument equipped with the nanoparticle tracking
analysis (NTA) 2.0 analytic software. B. Representative cytofluorimetric
analysis performed by Guava easyCyte Flow Cytometer of EVs shed by
CD105+ CSCs and CD105- TCs and analyzed with InCyte software. The
following markers were evaluated: CD44, CD105, α5 integrin, α6 integrin,
CD73, CD29, CD90 and CD146. (DOCX 451 kb)
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